APO Research
Talk to an analyst

APO RESEARCH · REPORT

Viral Vector Vaccines

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Viral Vector Vaccines Industry Growth and Trends Forecast to 2032

22 December 202598 pages

Choose your research edition.

Industry ResearchViral Vector Vaccines Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Viral Vector Vaccines Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Viral Vector Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Viral Vector Vaccines Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Viral Vector Vaccines Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Viral Vector Vaccines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Viral Vector Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Viral Vector Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Viral Vector Vaccines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Viral Vector Vaccines include Advanced Bioscience Laboratories, Boehringer Ingelheim, Brammer Bio, Creative Biogene, GE Healthcare, Pfizer and Sanofi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Viral Vector Vaccines market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Viral Vector Vaccines market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Viral Vector Vaccines market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Viral Vector Vaccines.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Viral Vector Vaccines market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Viral Vector Vaccines Market by Company

Advanced Bioscience Laboratories

Boehringer Ingelheim

Brammer Bio

Creative Biogene

GE Healthcare

Pfizer

Sanofi

Viral Vector Vaccines Segment by Type

Adenovirus

Fowlpox Virus

Vaccinia Virus Vectors

Attenuated Yellow Fever

Others

Viral Vector Vaccines Segment by Application

Hospitals

Clinics

Others

Viral Vector Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Viral Vector Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Viral Vector Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Viral Vector Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Viral Vector Vaccines manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Viral Vector Vaccines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Adenovirus Table 2. Major Company of Fowlpox Virus Table 3. Major Company of Vaccinia Virus Vectors Table 4. Major Company of Attenuated Yellow Fever Table 5. Major Company of Others Table 6. Global Viral Vector Vaccines Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Viral Vector Vaccines Sales by Type (2021-2026) & (k units) Table 8. Global Viral Vector Vaccines Sales Market Share in Volume by Type (2021-2026) Table 9. Global Viral Vector Vaccines Sales by Type (2021-2026) & (US$ Million) Table 10. Global Viral Vector Vaccines Sales Market Share in Value by Type (2021-2026) Table 11. Global Viral Vector Vaccines Price by Type (2021-2026) & (US$/unit) Table 12. Global Viral Vector Vaccines Sales by Type (2027-2032) & (k units) Table 13. Global Viral Vector Vaccines Sales Market Share in Volume by Type (2027-2032) Table 14. Global Viral Vector Vaccines Sales by Type (2027-2032) & (US$ Million) Table 15. Global Viral Vector Vaccines Sales Market Share in Value by Type (2027-2032) Table 16. Global Viral Vector Vaccines Price by Type (2027-2032) & (US$/unit) Table 17. North America Viral Vector Vaccines Sales by Type (2021-2026) & (k units) Table 18. North America Viral Vector Vaccines Sales by Type (2021-2026) & (US$ Million) Table 19. Europe Viral Vector Vaccines Sales by Type (2021-2026) & (k units) Table 20. Europe Viral Vector Vaccines Sales by Type (2021-2026) & (US$ Million) Table 21. Asia-Pacific Viral Vector Vaccines Sales by Type (2021-2026) & (k units) Table 22. Asia-Pacific Viral Vector Vaccines Sales by Type (2021-2026) & (US$ Million) Table 23. Latin America Viral Vector Vaccines Sales by Type (2021-2026) & (k units) Table 24. Latin America Viral Vector Vaccines Sales by Type (2021-2026) & (US$ Million) Table 25. Middle East and Africa Viral Vector Vaccines Sales by Type (2021-2026) & (k units) Table 26. Middle East and Africa Viral Vector Vaccines Sales by Type (2021-2026) & (US$ Million) Table 27. Viral Vector Vaccines Industry Trends Table 28. Viral Vector Vaccines Industry Drivers Table 29. Viral Vector Vaccines Industry Opportunities and Challenges Table 30. Viral Vector Vaccines Industry Restraints Table 31. Global Viral Vector Vaccines Sales Revenue by Company (US$ Million) & (2021-2026) Table 32. Global Viral Vector Vaccines Revenue Market Share by Company (2021-2026) Table 33. Global Viral Vector Vaccines Sales by Company (2021-2026) & (k units) Table 34. Global Viral Vector Vaccines Sales Share by Company (2021-2026) Table 35. Global Viral Vector Vaccines Market Price by Company (2021-2026) & (US$/unit) Table 36. Global Viral Vector Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026 Table 37. Global Viral Vector Vaccines Major Company Production Sites and Headquarters Table 38. Global Viral Vector Vaccines Company, Product Type & Application Table 39. Global Viral Vector Vaccines Company Establishment Date Table 40. Global Company Market Concentration Ratio (CR5 and HHI) Table 41. Global Viral Vector Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 42. Global Viral Vector Vaccines Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 43. Global Viral Vector Vaccines Sales by Region (2021-2026) & (k units) Table 44. Global Viral Vector Vaccines Sales Market Share in Volume by Region (2021-2026) Table 45. Global Viral Vector Vaccines Sales by Region (2021-2026) & (US$ Million) Table 46. Global Viral Vector Vaccines Sales Market Share in Value by Region (2021-2026) Table 47. Global Viral Vector Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 48. Global Viral Vector Vaccines Sales by Region (2027-2032) & (k units) Table 49. Global Viral Vector Vaccines Sales Market Share in Volume by Region (2027-2032) Table 50. Global Viral Vector Vaccines Sales by Region (2027-2032) & (US$ Million) Table 51. Global Viral Vector Vaccines Sales Market Share in Value by Region (2027-2032) Table 52. Global Viral Vector Vaccines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2027-2032) Table 53. Global Viral Vector Vaccines Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 54. Global Viral Vector Vaccines Sales by Application (2021-2026) & (k units) Table 55. Global Viral Vector Vaccines Sales Market Share in Volume by Application (2021-2026) Table 56. Global Viral Vector Vaccines Sales by Application (2021-2026) & (US$ Million) Table 57. Global Viral Vector Vaccines Sales Market Share in Value by Application (2021-2026) Table 58. Global Viral Vector Vaccines Price by Application (2021-2026) & (US$/unit) Table 59. Global Viral Vector Vaccines Sales by Application (2027-2032) & (k units) Table 60. Global Viral Vector Vaccines Sales Market Share in Volume by Application (2027-2032) Table 61. Global Viral Vector Vaccines Sales by Application (2027-2032) & (US$ Million) Table 62. Global Viral Vector Vaccines Sales Market Share in Value by Application (2027-2032) Table 63. Global Viral Vector Vaccines Price by Application (2027-2032) & (US$/unit) Table 64. North America Viral Vector Vaccines Sales by Application (2021-2026) & (k units) Table 65. North America Viral Vector Vaccines Sales by Application (2021-2026) & (US$ Million) Table 66. Europe Viral Vector Vaccines Sales by Application (2021-2026) & (k units) Table 67. Europe Viral Vector Vaccines Sales by Application (2021-2026) & (US$ Million) Table 68. Asia-Pacific Viral Vector Vaccines Sales by Application (2021-2026) & (k units) Table 69. Asia-Pacific Viral Vector Vaccines Sales by Application (2021-2026) & (US$ Million) Table 70. Latin America Viral Vector Vaccines Sales by Application (2021-2026) & (k units) Table 71. Latin America Viral Vector Vaccines Sales by Application (2021-2026) & (US$ Million) Table 72. Middle East and Africa Viral Vector Vaccines Sales by Application (2021-2026) & (k units) Table 73. Middle East and Africa Viral Vector Vaccines Sales by Application (2021-2026) & (US$ Million) Table 74. Advanced Bioscience Laboratories Company Information Table 75. Advanced Bioscience Laboratories Business Overview Table 76. Advanced Bioscience Laboratories Viral Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Advanced Bioscience Laboratories Viral Vector Vaccines Product Portfolio Table 78. Advanced Bioscience Laboratories Recent Development Table 79. Boehringer Ingelheim Company Information Table 80. Boehringer Ingelheim Business Overview Table 81. Boehringer Ingelheim Viral Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. Boehringer Ingelheim Viral Vector Vaccines Product Portfolio Table 83. Boehringer Ingelheim Recent Development Table 84. Brammer Bio Company Information Table 85. Brammer Bio Business Overview Table 86. Brammer Bio Viral Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Brammer Bio Viral Vector Vaccines Product Portfolio Table 88. Brammer Bio Recent Development Table 89. Creative Biogene Company Information Table 90. Creative Biogene Business Overview Table 91. Creative Biogene Viral Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Creative Biogene Viral Vector Vaccines Product Portfolio Table 93. Creative Biogene Recent Development Table 94. GE Healthcare Company Information Table 95. GE Healthcare Business Overview Table 96. GE Healthcare Viral Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. GE Healthcare Viral Vector Vaccines Product Portfolio Table 98. GE Healthcare Recent Development Table 99. Pfizer Company Information Table 100. Pfizer Business Overview Table 101. Pfizer Viral Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Pfizer Viral Vector Vaccines Product Portfolio Table 103. Pfizer Recent Development Table 104. Sanofi Company Information Table 105. Sanofi Business Overview Table 106. Sanofi Viral Vector Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Sanofi Viral Vector Vaccines Product Portfolio Table 108. Sanofi Recent Development Table 109. North America Viral Vector Vaccines Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 110. North America Viral Vector Vaccines Sales by Country (2021-2026) & (k units) Table 111. North America Viral Vector Vaccines Sales Market Share by Country (2021-2026) Table 112. North America Viral Vector Vaccines Sales Forecast by Country (2027-2032) & (k units) Table 113. North America Viral Vector Vaccines Sales Market Share Forecast by Country (2027-2032) Table 114. North America Viral Vector Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 115. North America Viral Vector Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 116. North America Viral Vector Vaccines Market Share by Country (2021-2026) Table 117. North America Viral Vector Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 118. North America Viral Vector Vaccines Market Share Forecast by Country (2027-2032) Table 119. Europe Viral Vector Vaccines Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 120. Europe Viral Vector Vaccines Sales by Country (2021-2026) & (k units) Table 121. Europe Viral Vector Vaccines Sales Market Share by Country (2021-2026) Table 122. Europe Viral Vector Vaccines Sales Forecast by Country (2027-2032) & (k units) Table 123. Europe Viral Vector Vaccines Sales Market Share Forecast by Country (2027-2032) Table 124. Europe Viral Vector Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 125. Europe Viral Vector Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 126. Europe Viral Vector Vaccines Market Share by Country (2021-2026) Table 127. Europe Viral Vector Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 128. Europe Viral Vector Vaccines Market Share Forecast by Country (2027-2032) Table 129. Asia-Pacific Viral Vector Vaccines Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 130. Asia-Pacific Viral Vector Vaccines Sales by Country (2021-2026) & (k units) Table 131. Asia-Pacific Viral Vector Vaccines Sales Market Share by Country (2021-2026) Table 132. Asia-Pacific Viral Vector Vaccines Sales Forecast by Country (2027-2032) & (k units) Table 133. Asia-Pacific Viral Vector Vaccines Sales Market Share Forecast by Country (2027-2032) Table 134. Asia-Pacific Viral Vector Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 135. Asia-Pacific Viral Vector Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 136. Asia-Pacific Viral Vector Vaccines Market Share by Country (2021-2026) Table 137. Asia-Pacific Viral Vector Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 138. Asia-Pacific Viral Vector Vaccines Market Share Forecast by Country (2027-2032) Table 139. Latin America Viral Vector Vaccines Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 140. Latin America Viral Vector Vaccines Sales by Country (2021-2026) & (k units) Table 141. Latin America Viral Vector Vaccines Sales Market Share by Country (2021-2026) Table 142. Latin America Viral Vector Vaccines Sales Forecast by Country (2027-2032) & (k units) Table 143. Latin America Viral Vector Vaccines Sales Market Share Forecast by Country (2027-2032) Table 144. Latin America Viral Vector Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 145. Latin America Viral Vector Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 146. Latin America Viral Vector Vaccines Market Share by Country (2021-2026) Table 147. Latin America Viral Vector Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 148. Latin America Viral Vector Vaccines Market Share Forecast by Country (2027-2032) Table 149. Middle East and Africa Viral Vector Vaccines Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 150. Middle East and Africa Viral Vector Vaccines Sales by Country (2021-2026) & (k units) Table 151. Middle East and Africa Viral Vector Vaccines Sales Market Share by Country (2021-2026) Table 152. Middle East and Africa Viral Vector Vaccines Sales Forecast by Country (2027-2032) & (k units) Table 153. Middle East and Africa Viral Vector Vaccines Sales Market Share Forecast by Country (2027-2032) Table 154. Middle East and Africa Viral Vector Vaccines Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 155. Middle East and Africa Viral Vector Vaccines Market Size by Country (2021-2026) & (US$ Million) Table 156. Middle East and Africa Viral Vector Vaccines Market Share by Country (2021-2026) Table 157. Middle East and Africa Viral Vector Vaccines Market Size Forecast by Country (2027-2032) & (US$ Million) Table 158. Middle East and Africa Viral Vector Vaccines Market Share Forecast by Country (2027-2032) Table 159. Key Raw Materials Table 160. Raw Materials Key Suppliers Table 161. Viral Vector Vaccines Distributors List Table 162. Viral Vector Vaccines Customers List Table 163. Research Programs/Design for This Report Table 164. Authors List of This Report Table 165. Secondary Sources Table 166. Primary Sources List of Figures Figure 1. Viral Vector Vaccines Image Figure 2. Global Viral Vector Vaccines Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Viral Vector Vaccines Market Size (2021-2032) & (US$ Million) Figure 4. Global Viral Vector Vaccines Sales (2021-2032) & (k units) Figure 5. Adenovirus Image Figure 6. Global Adenovirus Sales YoY Growth (2021-2032) & (k units) Figure 7. Fowlpox Virus Image Figure 8. Global Fowlpox Virus Sales YoY Growth (2021-2032) & (k units) Figure 9. Vaccinia Virus Vectors Image Figure 10. Global Vaccinia Virus Vectors Sales YoY Growth (2021-2032) & (k units) Figure 11. Attenuated Yellow Fever Image Figure 12. Global Attenuated Yellow Fever Sales YoY Growth (2021-2032) & (k units) Figure 13. Others Image Figure 14. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 15. Global Viral Vector Vaccines Market Size Overview by Type (2021-2032) & (US$ Million) Figure 16. Global Viral Vector Vaccines Market Share by Type 2025 VS 2032 Figure 17. North America Viral Vector Vaccines Sales Market Share in Volume by Type in 2025 Figure 18. North America Viral Vector Vaccines Sales Market Share in Value by Type in 2025 Figure 19. Europe Viral Vector Vaccines Sales Market Share in Volume by Type in 2025 Figure 20. Europe Viral Vector Vaccines Sales Market Share in Value by Type in 2025 Figure 21. Asia-Pacific Viral Vector Vaccines Sales Market Share in Volume by Type in 2025 Figure 22. Asia-Pacific Viral Vector Vaccines Sales Market Share in Value by Type in 2025 Figure 23. Latin America Viral Vector Vaccines Sales Market Share in Volume by Type in 2025 Figure 24. Latin America Viral Vector Vaccines Sales Market Share in Value by Type in 2025 Figure 25. Middle East and Africa Viral Vector Vaccines Sales Market Share in Volume by Type in 2025 Figure 26. Middle East and Africa Viral Vector Vaccines Sales Market Share in Value by Type in 2025 Figure 27. Global Top 5 and 10 Viral Vector Vaccines Players Market Share by Revenue in 2025 Figure 28. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Hospitals Image Figure 30. Global Hospitals Sales YoY Growth (2021-2032) & (k units) Figure 31. Clinics Image Figure 32. Global Clinics Sales YoY Growth (2021-2032) & (k units) Figure 33. Others Image Figure 34. Global Others Sales YoY Growth (2021-2032) & (k units) Figure 35. Global Viral Vector Vaccines Market Size Overview by Application (2021-2032) & (US$ Million) Figure 36. Global Viral Vector Vaccines Market Share by Application 2025 VS 2032 Figure 37. North America Viral Vector Vaccines Sales Market Share in Volume by Application in 2025 Figure 38. North America Viral Vector Vaccines Sales Market Share in Value by Application in 2025 Figure 39. Europe Viral Vector Vaccines Sales Market Share in Volume by Application in 2025 Figure 40. Europe Viral Vector Vaccines Sales Market Share in Value by Application in 2025 Figure 41. Asia-Pacific Viral Vector Vaccines Sales Market Share in Volume by Application in 2025 Figure 42. Asia-Pacific Viral Vector Vaccines Sales Market Share in Value by Application in 2025 Figure 43. Latin America Viral Vector Vaccines Sales Market Share in Volume by Application in 2025 Figure 44. Latin America Viral Vector Vaccines Sales Market Share in Value by Application in 2025 Figure 45. Middle East and Africa Viral Vector Vaccines Sales Market Share in Volume by Application in 2025 Figure 46. Middle East and Africa Viral Vector Vaccines Sales Market Share in Value by Application in 2025 Figure 47. North America Viral Vector Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 48. North America Viral Vector Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. North America Viral Vector Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. North America Viral Vector Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Europe Viral Vector Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 52. Europe Viral Vector Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Viral Vector Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Europe Viral Vector Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Asia-Pacific Viral Vector Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 56. Asia-Pacific Viral Vector Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Viral Vector Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Asia-Pacific Viral Vector Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Latin America Viral Vector Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 60. Latin America Viral Vector Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Viral Vector Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Latin America Viral Vector Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Middle East and Africa Viral Vector Vaccines Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 64. Middle East and Africa Viral Vector Vaccines Sales Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Viral Vector Vaccines Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 66. Middle East and Africa Viral Vector Vaccines Market Share by Country: 2021 VS 2025 VS 2032 Figure 67. Viral Vector Vaccines Value Chain Figure 68. Key Raw Materials Price Figure 69. Manufacturing Cost Structure Figure 70. Viral Vector Vaccines Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Adenovirus
  • Fowlpox Virus
  • Vaccinia Virus Vectors
  • Attenuated Yellow Fever
  • Others
Applications
  • Hospitals
  • Clinics
  • Others
Companies covered
  • Advanced Bioscience Laboratories
  • Boehringer Ingelheim
  • Brammer Bio
  • Creative Biogene
  • GE Healthcare
  • Pfizer
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Viral Vector Vaccines Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Viral Vector Vaccines Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Viral Vector Vaccines Market by Type
  6. 1.3.1 Adenovirus
  7. 1.3.2 Fowlpox Virus
  8. 1.3.3 Vaccinia Virus Vectors
  9. 1.3.4 Attenuated Yellow Fever
  10. 1.3.5 Others
  11. 1.4 Global Viral Vector Vaccines Market Size by Type
  12. 1.4.1 Global Viral Vector Vaccines Market Size Overview by Type (2021-2032)
  13. 1.4.2 Global Viral Vector Vaccines Historic Market Size Review by Type (2021-2026)
  14. 1.4.3 Global Viral Vector Vaccines Forecasted Market Size by Type (2027-2032)
  15. 1.5 Key Regions Market Size by Type
  16. 1.5.1 North America Viral Vector Vaccines Sales Breakdown by Type (2021-2026)
  17. 1.5.2 Europe Viral Vector Vaccines Sales Breakdown by Type (2021-2026)
  18. 1.5.3 Asia-Pacific Viral Vector Vaccines Sales Breakdown by Type (2021-2026)
  19. 1.5.4 South America Viral Vector Vaccines Sales Breakdown by Type (2021-2026)
  20. 1.5.5 Middle East and Africa Viral Vector Vaccines Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Viral Vector Vaccines Industry Trends
  2. 2.2 Viral Vector Vaccines Industry Drivers
  3. 2.3 Viral Vector Vaccines Industry Opportunities and Challenges
  4. 2.4 Viral Vector Vaccines Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Viral Vector Vaccines Revenue (2021-2026)
  2. 3.2 Global Top Players by Viral Vector Vaccines Sales (2021-2026)
  3. 3.3 Global Top Players by Viral Vector Vaccines Price (2021-2026)
  4. 3.4 Global Viral Vector Vaccines Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Viral Vector Vaccines Major Company Production Sites & Headquarters
  6. 3.6 Global Viral Vector Vaccines Company, Product Type & Application
  7. 3.7 Global Viral Vector Vaccines Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Viral Vector Vaccines Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Viral Vector Vaccines Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Viral Vector Vaccines Tier 1, Tier 2, and Tier 3
4 Viral Vector Vaccines Regional Status and Outlook
  1. 4.1 Global Viral Vector Vaccines Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Viral Vector Vaccines Historic Market Size by Region
  3. 4.2.1 Global Viral Vector Vaccines Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Viral Vector Vaccines Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Viral Vector Vaccines Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Viral Vector Vaccines Forecasted Market Size by Region
  7. 4.3.1 Global Viral Vector Vaccines Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Viral Vector Vaccines Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Viral Vector Vaccines Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Viral Vector Vaccines by Application
  1. 5.1 Viral Vector Vaccines Market by Application
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.1.3 Others
  5. 5.2 Global Viral Vector Vaccines Market Size by Application
  6. 5.2.1 Global Viral Vector Vaccines Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Viral Vector Vaccines Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Viral Vector Vaccines Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Viral Vector Vaccines Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Viral Vector Vaccines Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Viral Vector Vaccines Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Viral Vector Vaccines Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Viral Vector Vaccines Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Advanced Bioscience Laboratories
  2. 6.1.1 Advanced Bioscience Laboratories Company Information
  3. 6.1.2 Advanced Bioscience Laboratories Business Overview
  4. 6.1.3 Advanced Bioscience Laboratories Viral Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Advanced Bioscience Laboratories Viral Vector Vaccines Product Portfolio
  6. 6.1.5 Advanced Bioscience Laboratories Recent Developments
  7. 6.2 Boehringer Ingelheim
  8. 6.2.1 Boehringer Ingelheim Company Information
  9. 6.2.2 Boehringer Ingelheim Business Overview
  10. 6.2.3 Boehringer Ingelheim Viral Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Boehringer Ingelheim Viral Vector Vaccines Product Portfolio
  12. 6.2.5 Boehringer Ingelheim Recent Developments
  13. 6.3 Brammer Bio
  14. 6.3.1 Brammer Bio Company Information
  15. 6.3.2 Brammer Bio Business Overview
  16. 6.3.3 Brammer Bio Viral Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Brammer Bio Viral Vector Vaccines Product Portfolio
  18. 6.3.5 Brammer Bio Recent Developments
  19. 6.4 Creative Biogene
  20. 6.4.1 Creative Biogene Company Information
  21. 6.4.2 Creative Biogene Business Overview
  22. 6.4.3 Creative Biogene Viral Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Creative Biogene Viral Vector Vaccines Product Portfolio
  24. 6.4.5 Creative Biogene Recent Developments
  25. 6.5 GE Healthcare
  26. 6.5.1 GE Healthcare Company Information
  27. 6.5.2 GE Healthcare Business Overview
  28. 6.5.3 GE Healthcare Viral Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 GE Healthcare Viral Vector Vaccines Product Portfolio
  30. 6.5.5 GE Healthcare Recent Developments
  31. 6.6 Pfizer
  32. 6.6.1 Pfizer Company Information
  33. 6.6.2 Pfizer Business Overview
  34. 6.6.3 Pfizer Viral Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Pfizer Viral Vector Vaccines Product Portfolio
  36. 6.6.5 Pfizer Recent Developments
  37. 6.7 Sanofi
  38. 6.7.1 Sanofi Company Information
  39. 6.7.2 Sanofi Business Overview
  40. 6.7.3 Sanofi Viral Vector Vaccines Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Sanofi Viral Vector Vaccines Product Portfolio
  42. 6.7.5 Sanofi Recent Developments
7 North America by Country
  1. 7.1 North America Viral Vector Vaccines Sales by Country
  2. 7.1.1 North America Viral Vector Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Viral Vector Vaccines Sales by Country (2021-2026)
  4. 7.1.3 North America Viral Vector Vaccines Sales Forecast by Country (2027-2032)
  5. 7.2 North America Viral Vector Vaccines Market Size by Country
  6. 7.2.1 North America Viral Vector Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Viral Vector Vaccines Market Size by Country (2021-2026)
  8. 7.2.3 North America Viral Vector Vaccines Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Viral Vector Vaccines Sales by Country
  2. 8.1.1 Europe Viral Vector Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Viral Vector Vaccines Sales by Country (2021-2026)
  4. 8.1.3 Europe Viral Vector Vaccines Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Viral Vector Vaccines Market Size by Country
  6. 8.2.1 Europe Viral Vector Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Viral Vector Vaccines Market Size by Country (2021-2026)
  8. 8.2.3 Europe Viral Vector Vaccines Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Viral Vector Vaccines Sales by Country
  2. 9.1.1 Asia-Pacific Viral Vector Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Viral Vector Vaccines Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Viral Vector Vaccines Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Viral Vector Vaccines Market Size by Country
  6. 9.2.1 Asia-Pacific Viral Vector Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Viral Vector Vaccines Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Viral Vector Vaccines Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Viral Vector Vaccines Sales by Country
  2. 10.1.1 South America Viral Vector Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Viral Vector Vaccines Sales by Country (2021-2026)
  4. 10.1.3 South America Viral Vector Vaccines Sales Forecast by Country (2027-2032)
  5. 10.2 South America Viral Vector Vaccines Market Size by Country
  6. 10.2.1 South America Viral Vector Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Viral Vector Vaccines Market Size by Country (2021-2026)
  8. 10.2.3 South America Viral Vector Vaccines Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Viral Vector Vaccines Sales by Country
  2. 11.1.1 Middle East and Africa Viral Vector Vaccines Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Viral Vector Vaccines Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Viral Vector Vaccines Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Viral Vector Vaccines Market Size by Country
  6. 11.2.1 Middle East and Africa Viral Vector Vaccines Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Viral Vector Vaccines Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Viral Vector Vaccines Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Viral Vector Vaccines Value Chain Analysis
  2. 12.1.1 Viral Vector Vaccines Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Viral Vector Vaccines Production Mode & Process
  7. 12.2 Viral Vector Vaccines Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Viral Vector Vaccines Distributors
  10. 12.2.3 Viral Vector Vaccines Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst